Pulished : October, 2018
ID: 119
Region: Global
Share on

The Cancer Vaccines Market Is Predicted To Reach USD 8.57 Billion By 2023 With A CAGR Of 17.11 % According To Market Data Forecast Report.

Pulished: October, 2018
ID: 119
Share on

The Cancer Vaccines Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Cancer Vaccine Market is estimated to be USD 3.89 Billion in 2018 and predicted to rise to USD 8.57 billion by the end of 2023 with a CAGR of 17.11%. The market categorized based on Cancer type, the market is segmented into Prostate, Cervical, Colorectal, Throat, and others. Based on Vaccine type, the market is segmented into Protein and Peptide based, Tumour cell, Dendritic cell, Genetic vaccines and Others. Based on End Users, the market is segmented into Cancer Treatment Centres and Research Institutes. Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.

The key factor that are driving the growth of the market are Rising number of people with cancer, increasing public awareness of vaccines, smoking and excessive alcoholic intake, presence of strong late-stage pipeline Vaccines, vendors' patient-assistance programs. Rising number of people with cancer, increasing public awareness of vaccines, smoking and excessive alcoholic intake, presence of strong late-stage pipeline Vaccines, vendors' patient-assistance programs are the major factors limiting the growth of the market.

North American region is projected to account the highest share in the market which is mainly driven by the increasing incidence of cancer and increasing patient pool in U.S. Asia-Pacific region is expected to account the highest CAGR during the forecast period due to increasing health care expenditure.

Major players that are influencing Global Cancer Vaccines  Market are Dendreon, GlaxoSmithKline and Merck. Other companies whose products are in pipeline stage are Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, AVAX Technologies, Bavarian  Nordic, Biothera, Celldex Therapeutics, CureVac, Galena Biopharma, Genexine, GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Inovio Pharmaceuticals, ISA Pharmaceuticals, Juvaris Biotherapeutics, NewLink Genetics, Northwest Biotherapeutics.

Browse through the full report at “http://www.marketdataforecast.com/market-reports/global-cancer-vaccines-market-1419/” and checkout our recent reports in the Therapeutics category at “http://www.marketdataforecast.com/research-reports/healthcare/therapeutics-11/”. For more insights and up-to-date industry news don’t forget subscribing to our newsletters.